One Million Transgenic Silkworms Being Deployed as Production Targets 10 Metric Tons per MonthDENVER, Feb. 18, 2026 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the undisputed global leader in the development and commercialization of spider silk, is entering what may prove to be the defining phase of its multi-decade develo ...

Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. After an optimistic quarter, equity markets corrected slightly in November. Although overall economic growth has been robust throughout the year, recent divergent data on consumer spending and the labor market have put doubt on future projections. This pattern has become somewhat familiar over the past few years, as conflicting economic data has become the norm. As for the Fund’s ...

Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China’s growing cell therapy market and supports cross-border partnerships HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri”, the “Company”, “we”, “our” or “us”) (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its ...

- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society -  - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of infection, and no unprovoked structural failures - - Long-term durability results showed no dilatation nor narrowing of Symvess diameter out to 36 months - DURHAM, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing ...

Company Overview - Citi's newly appointed CFO, Gonzalo Luchetti, brings a strategic operator background rather than a traditional finance path, reflecting a shift in what companies seek in CFOs [1][5] - Luchetti will succeed Mark Mason, who will transition to an executive vice chair role and aims for CEO opportunities outside Citi by the end of 2026 [2] Leadership Experience - Luchetti has been with Citi since 2006 and has led U.S. Personal Banking since 2021, showcasing extensive global experience across various markets [3][4] - His background includes overseeing retail banking and consumer franchises in multiple regions, including Latin America, the U.S., EMEA, and Asia Pacific [4] Financial Performance and Strategy - Citi reported a profitable fourth quarter for 2025, with Luchetti emphasizing the importance of driving consistent, higher returns and maintaining strong risk and control practices [5][8] - The company aims for a 10% to 11% Return on Tangible Common Equity (RoTCE) in 2026, with net interest income projected to increase by 5%–6% [8] Evolving CFO Role - The role of CFO is evolving, with boards now seeking candidates who can lead technology transformation and navigate complex geopolitical and market challenges [6][7] - Luchetti's appointment aligns with the trend of companies favoring operator-CFOs who can influence enterprise-wide strategies [9]

Core Insights - Ocugen, Inc. is set to host a conference call and live webcast on March 4, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and provide a business update [1] - A pre-market earnings announcement will be issued on the same day, with details for participation provided [2] Company Overview - Ocugen, Inc. is a biotechnology leader specializing in gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [3] - The company is developing programs for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, which affect millions globally [3]

Core Viewpoint - Immunocore Holdings plc will report its financial results for the fourth quarter and full year 2025 on February 25, 2026, and will host a teleconference to discuss these results and provide a business update [1][2]. Company Overview - Immunocore is a commercial-stage biotechnology company focused on developing TCR bispecific immunotherapies, known as ImmTAX, aimed at treating various diseases including cancer, autoimmune diseases, and infectious diseases [4]. - The company has a robust pipeline in multiple therapeutic areas, with both clinical and pre-clinical programs [4]. - Its leading oncology TCR therapeutic, KIMMTRAK, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several regions including the US, EU, Canada, Australia, and the UK [4]. Conference Call Details - The live teleconference will take place at 8:00 a.m. EST (1:00 p.m. GMT) and will be accessible via the company's website [2][3]. - A replay of the event will be available for a limited time after the live call [3]. Contact Information - The company has provided contact details for communications and investor relations, including names, phone numbers, and email addresses for inquiries [5].

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - February 18, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement off ...

In the race to lead the innovation narrative, the US healthcare industry needs to actively consider systemic changes to contend with the growing competition from China, say industry experts. At the glitzy event organised by the lobbying group PhRMA on 17 February in Washington DC, several administration leaders mingled with leading pharma and biotech executives to discuss the latest trends and challenges in the pharmaceutical sector. The chief topic on the agenda for all was China; with PhRMA and others ...

ImmunityBio, Inc. ( IBRX ) stock has been on a very bullish run. The investor confidence comes from the potential of a chemo‑free immunotherapy platform, which is led by Anktiva. The short idea here is that Anktiva is an IL‑15 superagonist that fuelsI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foun ...